RxDoctor Payments Data

Hector Preti, MD

Hematology & Oncology · Chicago, ILNPI 1861484628

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,190 of the $11,439 with a category attached, or 71.6%. 60 manufacturers reported payments, led by Exelixis Inc. at 29.0% of the total. Reporting peaked in 2019 at $3,919 and has fallen 75.5% since, to $959 in 2025.

$11,439in general payments, 2019–2025

Across 397 payments — averaging $28.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exelixis Inc.$3K
  • Novartis$974
  • Pfizer$596
  • Merck$435
  • Gilead$431
  • E.r. Squibb & Sons, L.L.C.$394
  • plus $5K from 54 others
$13,674in research payments, 2019–2025

Across 2 payments — averaging $6836.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Veloxis Pharmaceuticals, Inc.$14K

What the payments were for

  • Speaking & faculty fees$1,85016%
  • Travel & lodging$1,24511%
  • Food & beverage$8,19072%
  • Education$1531%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Exelixis Inc.11$3,323
Novartis51$974
Pfizer29$596
Merck21$435
Gilead(2 entities)20$431
E.r. Squibb & Sons, L.L.C.28$394
AstraZeneca16$364
Amgen15$299
Incyte Corporation15$277
Johnson & Johnson10$268
Daiichi Sankyo Inc.11$259
Astellas Pharma US Inc8$236
Takeda Pharmaceuticals U.S.A., Inc.10$236
Bayer9$226
Eisai Inc.11$224
Ipsen Biopharmaceuticals, Inc8$177
Bristol Myers Squibb6$152
EMD Serono, Inc.7$148
Seagen Inc.7$147
Genentech USA, Inc.7$129
Beigene USA, Inc.5$125
Tersera Therapeutics LLC6$123
Adaptive Biotechnologies Corporation5$110
Pharmaessentia USA Corporation3$102
Coherus Oncology, Inc.4$100
Sanofi4$95
Puma Biotechnology, Inc.5$86
Jazz Pharmaceuticals Inc.3$82
Regeneron Healthcare Solutions, Inc.3$79
Rigel Pharmaceuticals, Inc.4$78
Morphosys, US Inc.3$71
Taiho Oncology, Inc.4$70
Boehringer Ingelheim3$66
EUSA Pharma (US) LLC3$65
Octapharma USA, Inc.2$60
AVEO Pharmaceuticals, Inc.2$52
Dendreon Pharmaceuticals LLC3$49
Genmab U.S., Inc.2$48
Epizyme, Inc.3$47
Verastem, Inc.1$44
Mirati Therapeutics, Inc.2$43
Array Biopharma Inc1$39
Organon4$35
GE HealthCare2$34
Deciphera Pharmaceuticals Inc.1$33
Syndax Pharmaceuticals, Inc.1$30
Pharmacosmos Therapeutics Inc.1$29
Karyopharm Therapeutics Inc.1$27
Spectrum Pharmaceuticals Inc.1$27
Menarini Silicon Biosystems, Inc.1$27
Beone Medicines USA, Inc.1$27
Inari Medical, Inc.1$24
Myriad Genetic Laboratories, Inc.1$24
Sirtex Medical Inc1$22
CTI Biopharma Corp.1$21
Tempus AI, Inc1$21
Servier Pharmaceuticals LLC1$20
Apellis Pharmaceuticals, Inc.1$20
Agios Pharmaceuticals, Inc.1$18
AbbVie1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,439 in reported general payments places this provider in the 75th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois →

Medicare billing

Part B allowed, 2024
$45,886
Medicare patients
165
Services billed
463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib13$196,293
BosulifBosutinib14$180,855
XareltoRivaroxaban14$22,774
EliquisApixaban24$19,256
Letrozole39$462
Dexamethasone19$365
Ondansetron OdtOndansetron22$307
Hydroxyurea25$293
Anastrozole18$214
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$140
Escitalopram Oxalate15$122
Prednisone17$84
Levothyroxine Sodium12$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerBosulif, Eliquis$596$200,11038 claims
Beigene USA, Inc.Brukinsa$125$196,29313 claims
Johnson & JohnsonXarelto$268$22,77414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Chicago

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →